Compare UCAR & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UCAR | TVRD |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | China | United States |
| Employees | N/A | 12 |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.5M | 34.6M |
| IPO Year | 2022 | N/A |
| Metric | UCAR | TVRD |
|---|---|---|
| Price | $1.35 | $2.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $50.00 | $29.50 |
| AVG Volume (30 Days) | ★ 480.7K | 45.6K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.04 | $2.75 |
| 52 Week High | $4.98 | $43.65 |
| Indicator | UCAR | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 46.86 | 34.12 |
| Support Level | $1.14 | N/A |
| Resistance Level | $1.68 | $4.32 |
| Average True Range (ATR) | 0.11 | 0.29 |
| MACD | -0.01 | -0.10 |
| Stochastic Oscillator | 22.77 | 2.34 |
U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.